Publications

Healing and Maintenance of Healing of Erosive Esophagitis

Alimentary Pharmacology and Therapeutics – 2016
Randomised clinical trial: vonoprazan, a novel potassium‐competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis

Ashida K et al.


World Journal of Gastroenterology – 2018
Maintenance for healed erosive esophagitis: Phase III comparison of vonoprazan with lansoprazole

Ashida K et al.


Gut – 2020
Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis

Xiao Y et al. 


DDW– 2020
Tu1321 – Vonoprazan 10 or 20 mg demonstrated superiority over lanzoprazole 15 mg in preventing relapse in Asian patients with endoscopic healing of erosive esophagitis: A Phase 3, Randomized, Double-Blind, Multicenter Study

Xiao Y et al. 


Eradication of H. pylori infection

Gut – 2016
Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study

Murakami K et al.

 

Eradication of H. pylori infection

Gastroenterology – 2016
Tu1333 Dual Therapy With Vonoprazan and Amoxicillin Is as Effective as Standard PPI-Based Triple Therapy With Amoxicillin and Clarithromycin or Metronidazole in Japan

Furuta T et al.


Gastroenterology – 2018
Tu1299 – Vonoprazan-Based Dual Therapy with Amoxicillin is as Effective as the Triple Therapy for the Eradication of H. Pylori

Furuta T et al.


Gut – 2020
Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: a multicentre randomised trial in Japan

Suzuki S et al.


Erosive Esophagitis

Alimentary Pharmacology & Therapeutics – 2018
Randomised clinical trial: vonoprazan versus lansoprazole for the initial relief of heartburn in patients with erosive oesophagitis

Oshima T et al.


DDW– 2020
Tu1362 – 2-year interim analysis results of VISION TRIAL: a randomized, open-label study to evaluate the long-term safety of vonoprazan as maintenance treatment in patients with erosive esophagitis

Uemura N et al. 

Alimentary Pharmacology & Therapeutics – 2015
Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects

Jenkins H et al.


Alimentary Pharmacology & Therapeutics – 2015
Acid‐inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects ‐ a randomised open‐label cross‐over study

Sakurai Y et al.


Alimentary Pharmacology & Therapeutics – 2016
Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype

Kagami T et al.


Alimentary Pharmacology & Therapeutics – 2020
Randomised trial of acid inhibition by vonoprazan 10/20 mg once daily vs rabeprazole 10/20 mg twice daily in healthy Japanese volunteers (SAMURAI pH study)

Takeuchi T et al.

Digestion – 2018
Current Status of Helicobacter pylori Diagnosis and Eradication Therapy in Japan Using a Nationwide Database

Deguchi H et al.

Journal of Neurogastroenterology and Motility – 2018
Potent Potassium-competitive Acid Blockers: A New Era for the Treatment of Acid-related Diseases

Oshima T, Miwa H.


Pharmacology & Therapeutics – 2016
Potassium-competitive acid blockers: Advanced therapeutic option for acid-related diseases

Inatomi et al.


Current Treatment Options in Gastroenterology – 2018
Potent Acid Suppression with PPIs and P-CABs: What’s New?

Hunt, R.H., Scarpignato, C.

*Vonoprazan is a product candidate that is under clinical study and that has not been approved for marketing by the U.S. Food and Drug Administration. No representation is made as to the safety or effectiveness of vonoprazan.

The publications contained in this section are provided for informational purposes only. The information contained in each publication is accurate only as of the date it was originally issued and is not controlled by Phathom. Phathom assumes no responsibility for the information or statements in such publications and disavows any obligation to update the information contained in such publications after the date of their issuance.